7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection

Mucosal immunity has a pivotal role in protection from respiratory viral infections.1 The current authors have showed substantial protection from omicron infection by high concentrations of nasal mucosal SARS-CoV-2 WT spike immunoglobulin-A (M-IgA) over a 4-week screening period.2 A sharp increase i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases Jg. 23; H. 2; S. 150 - 152
Hauptverfasser: Marking, Ulrika, Bladh, Oscar, Havervall, Sebastian, Svensson, Julia, Greilert-Norin, Nina, Aguilera, Katherina, Kihlgren, Martha, Salomonsson, Ann-Cristin, Månsson, Maja, Gallini, Radiosa, Kriegholm, Cecilia, Bacchus, Philip, Hober, Sophia, Gordon, Max, Blom, Kim, Smed-Sörensen, Anna, Åberg, Mikael, Klingström, Jonas, Thålin, Charlotte
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Elsevier Ltd 01.02.2023
Elsevier Limited
Schlagworte:
Antibodies
Antibodies, Neutralizing
Antibodies, Viral
Clinical Medicine
Correspondence
COVID-19
Humans
Immunity, Mucosal
Immunoglobulin A
Immunoglobulin G
Immunoglobulins
Infections
Infectious diseases
Infectious Medicine
Infektionsmedicin
Klinisk medicin
Medical and Health Sciences
Medicin och hälsovetenskap
Mucosal immunity
Risk management
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Viral diseases
Viral infections
ISSN:1473-3099, 1474-4457, 1474-4457
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mucosal immunity has a pivotal role in protection from respiratory viral infections.1 The current authors have showed substantial protection from omicron infection by high concentrations of nasal mucosal SARS-CoV-2 WT spike immunoglobulin-A (M-IgA) over a 4-week screening period.2 A sharp increase in M-IgA concentrations following BA.1 or BA.2 breakthrough infection in triple vaccinated health-care workers was also observed.2 Here, we present follow-up data with prospectively collected omicron infection rates and systemic and mucosal antibody concentrations from the same cohort (appendix pp 7–9, 12–14). The association between M-IgA concentrations at the 75th percentile or higher at enrolment and a reduced risk of symptomatic BA.1, BA.2, or BA.5 breakthrough infection remained over an 8-month follow-up period, with a hazard ratio (HR) of 0·55 (95% CI 0·35–0·87), much due to the initial risk difference (figure A). Serum WT spike-specific IgG (S-IgG) concentrations waned over 8 months following a third vaccine dose in all study participants (appendix p 10), concurrent with previous data.3 However, concentrations of nasal M-IgA in participants with previous SARS-CoV-2 infection, but without omicron breakthrough infection, remained above the amount associated to 65% protection2 over the 8-month study period (figure C).
Bibliographie:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
content type line 23
Contributed equally
ISSN:1473-3099
1474-4457
1474-4457
DOI:10.1016/S1473-3099(22)00834-9